These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35232398)

  • 21. Role of N-glycosylation in EGFR ectodomain ligand binding.
    Azimzadeh Irani M; Kannan S; Verma C
    Proteins; 2017 Aug; 85(8):1529-1549. PubMed ID: 28486782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.
    Koromyslova AD; Devant JM; Kilic T; Sabin CD; Malak V; Hansman GS
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structures of a llama VHH antibody BCD090-M2 targeting human ErbB3 receptor.
    Eliseev IE; Yudenko AN; Vysochinskaya VV; Svirina AA; Evstratyeva AV; Drozhzhachih MS; Krendeleva EA; Vladimirova AK; Nemankin TA; Ekimova VM; Ulitin AB; Lomovskaya MI; Yakovlev PA; Bukatin AS; Knyazev NA; Moiseenko FV; Chakchir OB
    F1000Res; 2018; 7():57. PubMed ID: 30430004
    [No Abstract]   [Full Text] [Related]  

  • 25. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival.
    Tabtimmai L; Suphakun P; Srisook P; Kiriwan D; Phanthong S; Kiatwuthinon P; Chaicumpa W; Choowongkomon K
    J Cell Biochem; 2019 Oct; 120(10):18077-18087. PubMed ID: 31172597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
    Ahadi M; Ghasemian H; Behdani M; Kazemi-Lomedasht F
    J Immunotoxicol; 2019 Dec; 16(1):34-42. PubMed ID: 30409071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
    Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
    J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization.
    Koromyslova AD; Hansman GS
    PLoS Pathog; 2017 Nov; 13(11):e1006636. PubMed ID: 29095961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.
    Modjtahedi H; Eccles SA; Box G; Styles J; Dean CJ
    Cell Biophys; 1993; 22(1-3):129-46. PubMed ID: 7534211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.
    van Driel PBAA; Boonstra MC; Slooter MD; Heukers R; Stammes MA; Snoeks TJA; de Bruijn HS; van Diest PJ; Vahrmeijer AL; van Bergen En Henegouwen PMP; van de Velde CJH; Löwik CWGM; Robinson DJ; Oliveira S
    J Control Release; 2016 May; 229():93-105. PubMed ID: 26988602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP.
    Lee HT; Park UB; Jeong TJ; Gu N; Lee SH; Kim Y; Heo YS
    Biochem Biophys Res Commun; 2021 Aug; 567():49-55. PubMed ID: 34144500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect.
    Chen T; Liu X; Hong H; Wei H
    J Transl Med; 2020 Oct; 18(1):376. PubMed ID: 33023595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
    Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
    J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unravelling the Molecular Basis of High Affinity Nanobodies against HIV p24: In Vitro Functional, Structural, and in Silico Insights.
    Gray ER; Brookes JC; Caillat C; Turbé V; Webb BLJ; Granger LA; Miller BS; McCoy LE; El Khattabi M; Verrips CT; Weiss RA; Duffy DM; Weissenhorn W; McKendry RA
    ACS Infect Dis; 2017 Jul; 3(7):479-491. PubMed ID: 28591513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
    Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
    MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
    Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
    Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
    van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.